Analytical Data
-
基因名
PTGFRN
- Application
-
别名
PTGFRN;MIC3;TSPAN29;CD9 antigen
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9P2B2
-
表达区间
1-879aa
-
氨基酸序列
MGRLASRPLLLALLSLALCRGRVVRVPTATLVRVVGTELVIPCNVSDYDGPSEQNFDWSFSSLGSSFVELASTWEVGFPAQLYQERLQRGEILLRRTANDAVELHIKNVQPSDQGHYKCSTPSTDATVQGNYEDTVQVKVLADSLHVGPSARPPPSLSLREGEPFELRCTAASASPLHTHLALLWEVHRGPARRSVLALTHEGRFHPGLGYEQRYHSGDVRLDTVGSDAYRLSVSRALSADQGSYRCIVSEWIAEQGNWQEIQEKAVEVATVVIQPSVLRAAVPKNVSVAEGKELDLTCNITTDRADDVRPEVTWSFSRMPDSTLPGSRVLARLDRDSLVHSSPHVALSHVDARSYHLLVRDVSKENSGYYYCHVSLWAPGHNRSWHKVAEAVSSPAGVGVTWLEPDYQVYLNASKVPGFADDPTELACRVVDTKSGEANVRFTVSWYYRMNRRSDNVVTSELLAVMDGDWTLKYGERSKQRAQDGDFIFSKEHTDTFNFRIQRTTEEDRGNYYCVVSAWTKQRNNSWVKSKDVFSKPVNIFWALEDSVLVVKARQPKPFFAAGNTFEMTCKVSSKNIKSPRYSVLIMAEKPVGDLSSPNETKYIISLDQDSVVKLENWTDASRVDGVVLEKVQEDEFRYRMYQTQVSDAGLYRCMVTAWSPVRGSLWREAATSLSNPIEIDFQTSGPIFNASVHSDTPSVIRGDLIKLFCIITVEGAALDPDDMAFDVSWFAVHSFGLDKAPVLLSSLDRKGIVTTSRRDWKSDLSLERVSVLEFLLQVHGSEDQDFGNYYCSVTPWVKSPTGSWQKEAEIHSKPVFITVKMDVLNAFKYPLLIGVGLSTVIGLLSCLIGYCSSHWCCKKEVQETRRERRRLMSMEMD
-
分子量
98.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PTGFRN (Prostaglandin F2 alpha Receptor Negative) protein has emerged as a significant focus in biomedical research due to its role in modulating various physiological and pathological processes, including inflammation, tissue repair, and cancer progression. Originally identified as a key player in the prostaglandin signaling pathway, PTGFRN has garnered interest for its potential implications in diverse disorders such as cardiovascular diseases, neurodegenerative conditions, and metabolic syndromes. The interest in recombinant PTGFRN protein primarily stems from its potential as a therapeutic target and its utility in mechanistic studies that elucidate its function in cellular signaling. By producing and characterizing recombinant PTGFRN, researchers aim to investigate its structure-function relationships, cellular interactions, and biochemical properties. These studies are crucial for understanding how PTGFRN influences cell behavior and contributes to disease mechanisms. Moreover, recombinant PTGFRN could serve as a valuable tool in the development of novel therapeutic strategies, offering insights into targeted treatments that could mitigate the effects of diseases related to dysregulated prostaglandin signaling. As such, ongoing research endeavors are focused on optimizing the production of recombinant PTGFRN, ensuring its stability and functionality for downstream applications. This could pave the way for advancements in both basic and applied sciences, potentially leading to breakthroughs in patient care and treatment regimens that leverage the unique properties of PTGFRN. Overall, the exploration of PTGFRN and its recombinant forms holds promise for uncovering new avenues in understanding and treating various health conditions, reinforcing the importance of continued investment in this area of research.












